Docetaxel Chemo Ups Survival in High-Risk Localized Prostate Cancer

THURSDAY, March 28, 2019 -- Adding docetaxel-based chemotherapy (CT) to standard treatment for high-risk nonmetastatic prostate cancer improves survival, according to a study published online March 12 in the Journal of Clinical Oncology. Seth A....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news